The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Ace revisited: A new target for structure-based drug design
Open accessAbstract
Current-generation angiotensin-converting enzyme (ACE) inhibitors are widely used for cardiovascular diseases, including high blood pressure, heart failure, heart attack and kidney failure, and have combined annual sales in excess of US $6 billion. However, the use of these ACE inhibitors, which were developed in the late 1970s and early 1980s, is hampered by common side effects. Moreover, we now know that ACE actually consists of two parts (called the N- and C-domains) that have different functions. Therefore, the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that might be safer and more effective. Here we discuss the structural features of current inhibitors and outline how next-generation ACE inhibitors could be designed by using the three-dimensional molecular structure of human testis ACE. The ACE structure provides a unique opportunity for rational drug design, based on a combination of in silico modelling using existing inhibitors as scaffolds and iterative lead optimization to drive the synthetic chemistry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rigat, B., Hubert, C., Alhenc-Gelas, F., Cambien, F., Corvol, P., & Soubrier, F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114844 · Cited by 3,767
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung
Cushman, D. W., & Cheung, H. S. (1971) · Biochemical Pharmacology · doi:10.1016/0006-2952(71)90292-9 · Cited by 2,625
Handbook of Proteolytic Enzymes
(2004) · Elsevier eBooks · doi:10.1016/c2009-0-03628-9 · Cited by 2,616
STUDIES ON EXPERIMENTAL HYPERTENSION
Goldblatt, H., Lynch, J., Hanzal, R. F., & Summerville, W. W. (1934) · Journal of Experimental Medicine · doi:10.1084/jem.59.3.347 · Cited by 2,142
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
Hypertension : pathophysiology, diagnosis, and management
Laragh, J. H., & Brenner, B. M. (1995) · Raven Press eBooks · Cited by 1,932
Ondetti, M. A., Rubin, B., & Cushman, D. W. (1977) · Science · doi:10.1126/science.191908 · Cited by 1,856
Zinc coordination, function, and structure of zinc enzymes and other proteins
Vallee, B. L., & Auld, D. S. (1990) · Biochemistry · doi:10.1021/bi00476a001 · Cited by 1,777
Wolf-Maier, K. (2003) · JAMA · doi:10.1001/jama.289.18.2363 · Cited by 1,737
Dickstein, K., & Kjekshus, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09895-1 · Cited by 1,203
The Handbook of proteolytic enzymes
Barrett, A. J., Rawlings, N. D., & Woessner, J. F. (1998) · Cited by 1,119
THE PREPARATION AND FUNCTION OF THE HYPERTENSIN-CONVERTING ENZYME
Skeggs, L. T., Kahn, J. R., & Shumway, N. P. (1956) · The Journal of Experimental Medicine · doi:10.1084/jem.103.3.295 · Cited by 1,032
Hypertension: Pathophysiology, Diagnosis, and Management
White, W. B. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460110128039 · Cited by 944
Integration of virtual and high-throughput screening
Bajorath, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd941 · Cited by 930
Cushman, D. W., Cheung, H. S., Sabo, E. F., & Ondetti, M. A. (1977) · Biochemistry · doi:10.1021/bi00644a014 · Cited by 892
Crystal structure of the human angiotensin-converting enzyme–lisinopril complex
Natesh, R., Schwager, S. L. U., Sturrock, E. D., & Acharya, K. R. (2003) · Nature · doi:10.1038/nature01370 · Cited by 888
Self-citationTwo putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning.
Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G., & Corvol, P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.24.9386 · Cited by 750
A new class of angiotensin-converting enzyme inhibitors
Patchett, A. A., Harris, E., Tristram, E. W., Wyvratt, M. J., Wu, M. T., Taub, D., Peterson, E. R., Ikeler, T. J., ten Broeke, J., Payne, L. G., et al. (1980) · Nature · doi:10.1038/288280a0 · Cited by 699
McKelvie, R. S., Yusuf, S., Pericak, D., Avezum, A., Burns, R. J., Probstfield, J., Tsuyuki, R. T., White, M., Rouleau, J., Latini, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.10.1056 · Cited by 692
Conversion of Angiotensin I to Angiotensin II
NG, K. K. F., & VANE, J. R. (1967) · Nature · doi:10.1038/216762a0 · Cited by 534
High-throughput crystallography for lead discovery in drug design
Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 530
Ondetti, M. A., Williams, N. J., Sabo, E., Pluscec, J., Weaver, E. R., & Kocy, O. (1971) · Biochemistry · doi:10.1021/bi00798a004 · Cited by 521
Enzymes of the Renin-Angiotensin System and their Inhibitors
Ondetti, M. A., & Cushman, D. W. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.001435 · Cited by 467
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Gainer, J. V., Morrow, J. D., Loveland, A., King, D. J., & Brown, N. J. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810293391804 · Cited by 443
Drugs targeting the renin–angiotensin–aldosterone system
Zaman, M. A., Oparil, S., & Calhoun, D. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd873 · Cited by 439
Page, I. H., & Helmer, O. M. (1940) · Journal of Experimental Medicine · doi:10.1084/jem.71.1.29 · Cited by 434
Hubert, C., Houot, A. M., Corvol, P., & Soubrier, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98626-6 · Cited by 426
Nussberger, J., Wuerzner, G., Jensen, C., & Brunner, H. R. (2002) · Hypertension · doi:10.1161/hy0102.102293 · Cited by 409
The angiotensin–converting enzyme gene family: genomics and pharmacology
Turner, A. J., & Hooper, N. M. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01994-5 · Cited by 406
The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
Wei, L., Alhenc-Gelas, F., Corvol, P., & Clauser, E. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31543-6 · Cited by 383
Nickenig, G., & Harrison, D. G. (2002) · Circulation · doi:10.1161/hc0302.102618 · Cited by 366
Angiotensin-converting enzyme and male fertility
Hagaman, J. R., Moyer, J. S., Bachman, E. S., Sibony, M., Magyar, P. L., Welch, J. E., Smithies, O., Krege, J. H., & O’Brien, D. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2552 · Cited by 340
Jaspard, E., Wei, L., & Alhenc-Gelas, F. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98378-x · Cited by 325
Fate of Angiotensin I in the Circulation
NG, K. K. F., & VANE, J. R. (1968) · Nature · doi:10.1038/218144a0 · Cited by 312
Ehlers, M. R., Fox, E. A., Strydom, D. J., & Riordan, J. F. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7741 · Cited by 292
Self-citationThe critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.
Esther, C. R., Marino, E. M., Howard, T. E., Machaud, A., Corvol, P., Capecchi, M. R., & Bernstein, K. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119419 · Cited by 272
β‐Amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?
Carson, J. A., & Turner, A. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00855.x · Cited by 261
Conversion of Angiotensin I to Angiotensin II by Cell-free Extracts of Dog Lung
BAKHLE, Y. S. (1968) · Nature · doi:10.1038/220919a0 · Cited by 258
Wei, L., Clauser, E., Alhenc-Gelas, F., & Corvol, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42224-7 · Cited by 256
Deddish, P. A., Marcic, B., Jackman, H. L., Wang, H.-Z., Skidgel, R. A., & Erdös, E. G. (1998) · Hypertension · doi:10.1161/01.hyp.31.4.912 · Cited by 244
Vasopeptidase inhibition and angio-oedema
Messerli, F. H., & Nussberger, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02596-4 · Cited by 223
Design of angiotensin converting enzyme inhibitors
Cushman, D. W., & Ondetti, M. A. (1999) · Nature Medicine · doi:10.1038/13423 · Cited by 213
Mutahi, M. W., Nittoli, T., Guo, L., & Sieburth, S. M. (2002) · Journal of the American Chemical Society · doi:10.1021/ja026158w · Cited by 196
Nickenig, G., & Harrison, D. G. (2002) · Circulation · doi:10.1161/hc0402.102619 · Cited by 196
Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A
Byers, L. D., & Wolfenden, R. (1973) · Biochemistry · doi:10.1021/bi00735a008 · Cited by 195
FERREIRA, S. H., GREENE, L. J., ALABASTER, V. A., BAKHLE, Y. S., & VANE, J. R. (1970) · Nature · doi:10.1038/225379a0 · Cited by 191
Guy, J. L., Jackson, R. M., Acharya, K. R., Sturrock, E. D., Hooper, N. M., & Turner, A. J. (2003) · Biochemistry · doi:10.1021/bi035268s · Cited by 189
Self-citationAminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors
Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., & Agostoni, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08914-6 · Cited by 181
Smith, C. G., & Vane, J. R. (2003) · The FASEB Journal · doi:10.1096/fj.03-0093life · Cited by 161
Georgiadis, D., Beau, F., Czarny, B., Cotton, J., Yiotakis, A., & Dive, V. (2003) · Circulation Research · doi:10.1161/01.res.0000081593.33848.fc · Cited by 157
Just the Beginning: Novel Functions for Angiotensin-Converting Enzymes
Eriksson, U., Danilczyk, U. G., & Penninger, J. M. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01255-1 · Cited by 148
Hydrolysis of Peptide Hormones by Endothelin-converting Enzyme-1
Johnson, G. D., Stevenson, T. I., & Ahn, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.7.4053 · Cited by 145
Minshall, R. D., Tan, F., Nakamura, F., Rabito, S. F., Becker, R. P., Marcic, B. M., & Erdös, E. G. (1997) · Circulation Research · doi:10.1161/01.res.81.5.848 · Cited by 141
Ehlers, M. R., & Riordan, J. F. (1991) · Biochemistry · doi:10.1021/bi00243a012 · Cited by 136
Self-citationHuman Performance: A Role for the ACE Genotype?
Jones, A., Montgomery, H., & Woods, D. R. (2002) · Exercise and Sport Sciences Reviews · doi:10.1097/00003677-200210000-00008 · Cited by 135
Plata, R., Cornejo, A., Arratia, C., Anabaya, A., Perna, A., Dimitrov, B. D., Remuzzi, G., & Ruggenenti, P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07812-1 · Cited by 131
Angiotensin Converting Enzyme Gene Insertion/Deletion Polymorphism and Cardiovascular Disease
Niu, T., Chen, X., & Xu, X. (2002) · Drugs · doi:10.2165/00003495-200262070-00001 · Cited by 119
Vasopeptidase Inhibition: A Double-Edged Sword?
Campbell, D. J. (2003) · Hypertension · doi:10.1161/01.hyp.0000054215.71691.16 · Cited by 116
Benzing, T. R., Fleming, I., Blaukat, A., Müller‐Esterl, W., & Busse, R. (1999) · Circulation · doi:10.1161/01.cir.99.15.2034 · Cited by 114
The genesis of high-throughput structure-based drug discovery using protein crystallography
Kühn, P., Wilson, K. P., Patch, M. G., & Stevens, R. C. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00361-7 · Cited by 111
Enhancement of Bradykinin and Resensitization of Its B2Receptor
Marcic, B. M., Deddish, P. A., Jackman, H. L., & Erdös, E. G. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.835 · Cited by 110
Omapatrilat—the story of Overture and Octave
Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00389-3 · Cited by 107 · cited 1×
“The clinical results with omapatrilat have had a sobering effect on the field 88 and have indicated that broad inhibition of vasoregulatory peptides should be approached with caution 89 .”
BackgroundWeber, M. A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06584-9 · Cited by 106
Tom, B., VRIES, R. D., Saxena, P. R., & Danser, A. H. J. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.95 · Cited by 105
Using ACE inhibitors appropriately.
Bicket, D. P. (2002) · PubMed · Cited by 103
Crystal structure of Drosophila angiotensin I‐converting enzyme bound to captopril and lisinopril1
Kim, H. M., Shin, D. R., Yoo, O. J., Lee, H., & Lee, J. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00128-5 · Cited by 103
Rhaleb, N., Peng, H., Harding, P., et al. (2001) · Hypertension · doi:10.1161/01.hyp.37.3.827 · Cited by 97
The Design and Properties of N‐Carboxyalkyldipeptide Inhibitors of Angiotensin‐Converting Enzyme
Patchett, A. A., & Cordes, E. H. (1985) · Advances in enzymology and related areas of molecular biology/Advances in enzymology and related subjects · doi:10.1002/9780470123034.ch1 · Cited by 95
Comparative pharmacology of H1 antihistamines: clinical relevance
Simons, F. E. R. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01436-5 · Cited by 93
Junot, C., Gonzales, M.-F., Ezan, É., Cotton, J., Vazeux, G., Michaud, A., Azizi, M., Vassiliou, S., Yiotakis, A., Corvol, P. L., et al. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29576-8 · Cited by 90
Howes, L. G., & Tran, D. (2002) · Drug Safety · doi:10.2165/00002018-200225020-00001 · Cited by 83
Hayashi, M. A. F., Murbach, A. F., Ianzer, D. A., Portaro, F. C. V., Prezoto, B. C., Fernandes, B. L., Silveira, P. F., Alberto-Silva, C., Pires, R. S., Britto, L. R., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01743.x · Cited by 78
Woodman, Z., Oppong, S. Y., Sarah, C. O. O. K., Hooper, N. M., Schwager, S. L. U., BRANDT, W. F., Ehlers, M. R., & Sturrock, E. D. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470711 · Cited by 76
Self-citationWilliams, T. A., Michaud, A., Houard, X., Chauvet, M. T., Soubrier, F., & Corvol, P. L. (1996) · Biochemical Journal · doi:10.1042/bj3180125 · Cited by 74
Structure-based screening and design in drug discovery
van Dongen, M. J. P., Weigelt, J., Uppenberg, J., Schultz, J., & Wikström, M. (2002) · Drug Discovery Today · doi:10.1016/s1359-6446(02)02233-x · Cited by 71
Ehlers, M. R., Schwager, S. L. U., Scholle, R. R., Manji, G. A., BRANDT, W. F., & Riordan, J. F. (1996) · Biochemistry · doi:10.1021/bi9602425 · Cited by 69
Self-citationDeglycosylation, processing and crystallization of human testis angiotensin-converting enzyme
Gordon, K., Redelinghuys, P., Schwager, S. L. U., Ehlers, M. R., Papageorgiou, A. C., NATESH, R., Acharya, K. R., & Sturrock, E. D. (2003) · Biochemical Journal · doi:10.1042/bj20021842 · Cited by 66
Self-citationThe Acer gene of Drosophila codes for an angiotensin-converting enzyme homologue
Taylor, C. A., Coates, D., & Shirras, A. D. (1996) · Gene · doi:10.1016/s0378-1119(96)00503-3 · Cited by 53
Angiotensin blockade for hypertension: a promise fulfilled
Brunner, H. R., & Gavras, H. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08062-5 · Cited by 49
Patchett, A. A. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020424z · Cited by 33
Contribution of bradykinin to the cardioprotective effects of ACE inhibitors
Murphey, L. J. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90062-9 · Cited by 32
Angiotensin-converting enzyme inhibitors.
Menard, J., & Patchett, A. (2001) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(01)56002-7 · Cited by 30
Effects of the N-Terminal Sequence of ACE on the Properties of Its C-Domain
Marcic, B. M., Deddish, P. A., Jackman, H. L., Erdös, E. G., & Tan, F. (2000) · Hypertension · doi:10.1161/01.hyp.36.1.116-a · Cited by 30
Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies
Lonn, E. (2003) · European Heart Journal Supplements · doi:10.1016/s1520-765x(03)90063-0 · Cited by 29
Thyroid autoimmunity and cardiovascular diseases
Aho, K., Gordin, A., Palosuo, T., Punsar, S., Valkeila, E., KARVONEN, M. J., Inkovaara, J., & Pasternack, A. I. (1984) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a061550 · Cited by 24
Brown, R. E., Quirk, J., & Kirkpatrick, P. N. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1039 · Cited by 23
Hypertension —Opportunities and Challenges
Hall, J. E. (2002) · Hypertension · doi:10.1161/hyp.39.1.1 · Cited by 18
Inflammation in early atherogenesis: impact of ACE inhibition
Caterina, R. D., & Manes, C. (2003) · European Heart Journal Supplements · doi:10.1093/oxfordjournals.ehjsupp.a000771 · Cited by 12
Sleight, P. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90074-x · Cited by 11
Cited by
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
Metadata
- Authors
- Acharya, K. R., Sturrock, E. D., Riordan, J. F., & Ehlers, M. R. W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 891-902
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1990840149
- Cited by
- 342
- References
- 91
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.